Immunotherapy duo shows promise against rare lung cancer in chinese trial
NCT ID NCT05136677
First seen Jan 24, 2026 · Last updated May 22, 2026 · Updated 19 times
Summary
This study tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard chemotherapy for Chinese patients with advanced pleural mesothelioma, a rare cancer of the lung lining. About 102 patients with inoperable disease took part. The main goal was to see if the immunotherapy combo helped patients live longer, while also checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA, MALIGNANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0001
Shanghai, Shanghai Municipality, 200030, China
-
Local Institution - 0003
Changchun, Jilin, 130021, China
-
Local Institution - 0004
Shenyang, Liaoning, 110042, China
-
Local Institution - 0005
Changsha, Hunan, 410013, China
-
Local Institution - 0006
Zhengzhou, Henan, 450003, China
-
Local Institution - 0007
Tianjin, Tianjin Municipality, 300052, China
-
Local Institution - 0009
Beijing, Beijing Municipality, 100142, China
-
Local Institution - 0010
Kunming, Yunnan, 650106, China
-
Local Institution - 0012
Ningbo, Zhejiang, 315010, China
-
Local Institution - 0013
Harbin, Heilongjiang, 150081, China
-
Local Institution - 0014
Hangzhou, Zhejiang, 310003, China
-
Local Institution - 0015
Yangzhou, Jiangsu, 225001, China
-
Local Institution - 0016
Ningbo, Zhejiang, 315041, China
-
Local Institution - 0018
Tianjin, Tianjin Municipality, 300060, China
-
Local Institution - 0020
Hangzhou, Zhejiang, 310005, China
-
Local Institution - 0021
Shenyang, Liaoning, 110044, China
-
Local Institution - 0023
Wuhan, Hunan, 430023, China
-
Local Institution - 0029
Chengdu, Sichuan, 610041, China
-
Local Institution - 0030
Qingdao, Shandong, 266003, China
-
Local Institution - 0033
Taiyuan, Shanxi, 030000, China
-
Local Institution - 0037
Jinan, Shandong, 250117, China
Conditions
Explore the condition pages connected to this study.